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Introduction: Capecitabine is a widely prescribed oral anticancer agent. We studied
medication adherence and explored its use in daily practice from a patients’ perspective.
Patients and Methods: Patients (n = 92) starting capecitabine were followed up
to five 3-week cycles. Adherence was assessed using a pill count, pharmacy data
and dosing information from the patients’ medical file. Self-reported adherence was
measured using the Medication Adherence Report Scale (MARS). At baseline and
during week 2 of cycles 1, 3, and 5, patients filled out questionnaires about quality
of life, symptoms, attitude toward medicines and disease and use in daily practice.
Simultaneously, blood samples were taken to determine the area under the curve
(AUC) of 5′-deoxy-5-fluorouridine (5′-DFUR), 5-fluorouracil (5-FU), and α-fluoro-β-alanine
(FBAL) by a population pharmacokinetic model. Associations between AUCs and
patient-reported symptoms were tested for cycles 3 and 5.
Results: Most patients (84/92; 91%) had an adherence rate of ≥95 and ≤105%. The
percentage of patients reporting any non-adherence behavior measured with MARS
increased from 16% at cycle 1 to 29% at cycle 5. Symptoms were reported frequently
and the dosing regimen was adjusted by the physician at least once in 62% of patients.
In multivariate analysis the probability of an adjustment increased with the number of
co-medication (OR 1.19, 95% CI: 1.03–1.39) and a stronger emotional response to the
disease (OR 1.32, 95% CI: 1.10–1.59). The AUC of 5′-DFUR was associated with weight
loss (OR 1.10, 95% CI: 1.01–1.19), AUC of FBAL with hand-foot syndrome (OR 0.90,
95% CI: 0.83–0.99), rhinorrhea (OR 1.21, 95% CI: 1.03–1.42 weight loss (OR 1.09, 95%
CI: 1.00–1.20) and depression (OR 0.90, 95% CI: 0.82–0.99). Side effects were reported
by one third of patients as the reason to discontinue treatment.
Conclusion: Adherence to capecitabine was generally high. Nevertheless, adherence
measured with MARS decreased over time Adherence management to support
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implementation of correct capecitabine use is specifically relevant in longer term
treatment. In addition, it appears that adverse event management is important to support
persistence. With the extending armamentarium of oral targeted anticancer agents and
prolonged treatment duration, we expect the issue of medication adherence of increasing
importance in oncology.
Keywords: capecitabine, medication adherence, patient-reported symptoms, dose adjustments,
pharmacokinetics, oral anticancer agent
INTRODUCTION
Capecitabine is registered for treatment of patients following
surgery of stage III (Dukes’ stage C) colon cancer in the adjuvant
setting, for treatment of metastatic colorectal cancer, first-line
treatment of advanced gastric cancer and for treatment of locally
advanced or metastatic breast cancer (European Medicines
Agency (EMEA), 2015). Capecitabine is an oral prodrug of
5-fluorouracil (5-FU). Oral administration is more convenient
and most patients prefer oral medication provided similar
efficacy (Liu et al., 1997; Borner et al., 2001). 5-FU has largely
been replaced by capecitabine, since the latter drug is considered
equally effective (Cassidy et al., 2002; Van Cutsem et al., 2004;
Twelves et al., 2005), has a generally better toxicity profile apart
from hand-foot syndrome (HFS) (Cassidy et al., 2002; Twelves
et al., 2005) and is more cost-effective (Cassidy et al., 2006;
Ward et al., 2006). Capecitabine is commonly prescribed in
a 3-week treatment cycle, with doses on days 1 through 14,
followed by a 7-day rest period. The dosing regimen is even
more complex as the capsules should be used twice daily within
30min after a meal with a 12-h interval. Furthermore, to obtain
the required dosage patients need to take several capsules (e.g.,
when prescribed a daily dose of 2300mg, a patient has to take
2 capsules of 500mg and 1 capsule of 150mg in the morning
and in the evening; European Medicines Agency (EMEA), 2015).
The starting dose depends on previous treatments, combination
with other cytotoxic agents, renal function, and knowledge
of dihydropyrimidine dehydrogenase (DPD) deficiency and
is calculated on the basis of the body surface area (BSA).
Dose reduction and/or delay are guided by the occurrence of
toxicity.
As a consequence of oral administration of anticancer agents
responsibility of intake has shifted toward patients and non-
adherence is an issue to deal with. Adherence to capecitabine,
appears to be higher (Macintosh et al., 2007; Mayer et al., 2009;
Regnier Denois et al., 2011; Simons et al., 2011; Winterhalder
et al., 2011; Bhattacharya et al., 2012; Krolop et al., 2013;
Patel et al., 2013; Thivat et al., 2013; Walter et al., 2013;
Timmers et al., 2014; Zahrina et al., 2014; De Figueiredo
and Forones, 2014) than adherence to long-term medication
in chronic disease (Sabaté, 2003; Osterberg and Blaschke,
2005). Assessment of adherence to capecitabine treatment is
challenging because of the dosing regimen which is complex
and the frequent necessity of individual adjustments. For
assessment of medication adherence it is essential to use a
method to distinguish patients’ non-adherence from physicians’
adjustments during treatment.
Several factors can be related to non-adherence (Verbrugghe
et al., 2013; Mathes et al., 2014). Toxicity from drugs is
an important factor in non-adherence (Verbrugghe et al.,
2013). Patient-reported symptoms are a better reflection of the
subjective daily health status than physician’s scoring systems
(Basch et al., 2009). When adverse events are assessed in relation
with adherence, it is consistent to study them from a patients’
point of view as patient-reported symptoms might have a
stronger relationship with patients’ non-adherence.
According to Leventhal’s common sense model (CSM)
patients’ perception of and beliefs about their illness are
important factors in their reactions and behavior to health
threats (McAndrew et al., 2008). Beliefs about medicines are also
associated with medication adherence (Horne et al., 2013) in
various diseases.
Pharmacokinetic behavior of capecitabine is complex and
there is considerable variability in metabolite concentrations
among patients caused by multiple factors (Reigner et al., 2001).
Gieschke et al. (2003) have demonstrated a relation between
systemic exposure to the capecitabine metabolites 5′-DFUR, 5-
FU, and FBAL and efficacy or toxicity. Yen-Revollo et al. (2008)
have given mounting evidence that HFS seems to be caused by
products of DPD-initiated catabolic degradation of 5-FU. With
the use of capecitabine in daily practice, drug exposure might be
a factor of influence on medication adherence.
The present study was designed to to get more insight into
patients’ experiences with the use of capecitabine in daily practice
and the various aspects that govern adherence. To that end, we
studied medication adherence in patients with cancer starting
the use of capecitabine and the influence of patients’ attitudes
and side-effects on adherence. Furthermore, we explored
possible relationships between patient characteristics, disease
characteristics, symptoms, quality of life, patients’ beliefs and
attitude toward disease andmedicines, dose adjustments, reasons
for discontinuation and exposure to 5′-DFUR, 5-FU, and FBAL
and adherence.
PATIENTS AND METHODS
Study Design
In this prospective observational cohort study (Timmers et al.,
2012), conducted between June 2010 and January 2012 in 10
Dutch hospitals, patients who started capecitabine treatment
were followed up to five 3-week treatment cycles. The study was
approved by the Medical Ethics review board of VU University
Medical Center (VUMC, Amsterdam, the Netherlands), as well
as the boards of each participating center. Written informed
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consent was obtained from all patients. The study was registered
in the Netherland Trial Register under number NTR2324 and the
protocol was published (Timmers et al., 2012).
Patients
Regardless of the indication, patients starting treatment with
capecitabine were eligible for participation. Exclusion criteria
were: age younger than 18 years and inability to fill out a Dutch
questionnaire.
Data Collection
Disease Characteristics and Dose Adjustments
Information on indication for treatment with capecitabine, BSA,
the starting dose, dose adjustments, and concomitant cytotoxic
agents was retrieved from the patient’s medical file. Adjustments
were categorized as: dose reduction (lowering the daily dose),
shortening of the period of use (less than 14 consecutive days
of capecitabine at the beginning of the 3-week cycle) and delay
(the next cycle starting more than 21 days after the start of the
previous cycle).
Medication Adherence
The overall adherence rate in the implementation phase was
assessed during the studied period with a pill count method
which corrects for the adjustments made by the physician.
We refer to this as the PPP-method (Pill count-Pharmacy
records-Patients’ file). Patients were contacted unannounced
by phone after finishing the fifth cycle or earlier when they
prematurely discontinued. They were asked to count their
remaining pills and were whether they had returned pills to the
pharmacy or disposed pills in any other way. Dispensing records
of the pharmacy (or pharmacies) and the initially prescribed
number of pills as well as all adjustments during use retrieved
from the patient’s medical file were collected. This information
was plotted in a calendar during the studied period (form start
till the moment of pill count). Adherence was expressed as
the percentage of the total amount in mg the patient used
in the studied period toward the total amount in mg the
patient was supposed to use in the studied period. This was
calculated by dividing the number of pills dispensed minus
the pill count by the initially prescribed capecitabine dosing
regimen minus adjustments of the dosing regimen (Figure 1).
In addition, medication adherence behavior was assessed by a
patient-reported questionnaire (Medication Adherence Report
Scale,MARS; Horne et al., 2001). Furthermore, the blood samples
were used to get insight into medication adherence. When
capecitabine nor one of its primary metabolites (5′-DFCR, 5′-
DFUR, 5-FU) could be detected in the period 20 min–12 h after
themoment of intake that was reported by the patient, the patient
was assumed to be non-adherent at that time-point.
Patient-Reported Questionnaires
Patients filled out a questionnaire at baseline and during
treatment, in the second week of cycles 1, 3, and 5. including
education, living status, occupation, all co-medication, quality
of life (SF-12) (Gandek et al., 1998), illness perceptions (Brief
IPQ) (Broadbent et al., 2006), patient’s beliefs about medicine
FIGURE 1 | PPP-method (Pill count-Pharmacy records-Patients’ file) to
measure the Adherence Rate.
in general and toward capecitabine (BMQ) (Horne et al., 1999).
adherence (MARS) (Horne et al., 2001), food intake in relation to
capecitabine intake and type and grade of symptoms. Symptoms
occurring in ≥1% of patients according to the European Public
Assessment Report (EPAR) of capecitabine (European Medicines
Agency (EMEA), 2015) were included in the questionnaire.
Answers could be scored on a 5 point Likert scale (not at
all, a little bit, rather, a lot, very much). Symptoms scored
as “a lot” or “very much” were considered as “severe.” When
a patient discontinued capecitabine treatment, the reasons for
discontinuation were enquired.
Exposure to Metabolites
A blood sample was collected in the second week of cycles
1, 3, and 5. The time of blood withdrawal and the time of
the last capecitabine intake were recorded. At each withdrawal
patient’s length and weight were documented. Blood samples
were analyzed by validated liquid chromatography/tandem mass
spectrometrymethods for plasma concentrations of capecitabine,
5′-DFCR, 5′-DFUR, 5-FU and FBAL (Deenen et al., 2013).
Alkaline phosphatase (AF) and creatinine concentrations were
analyzed from the same blood sample. Creatinine clearance was
calculated using the Cockcroft-Gault formula (Cockcroft and
Gault, 1976). For post-hoc estimation of the area under the
curve (AUC) of the metabolites, the data were incorporated
in the NONMEM program (version VI), using a population
pharmacokinetic model described by Gieschke et al. (2003).
Apart from the concentration of the metabolites 5′-DFUR, 5-FU,
and FBAL, the model required capecitabine dose, time between
intake of capecitabine and blood sample collection, BSA, AF
concentration and creatinine clearance to estimate the AUC.
Samples collected within 20 min after intake, those with an
unknown time-point of last capecitabine intake and undetectable
plasma levels of 5′-DFUR or 5-FU were excluded from further
analyses.
Statistical Methods
The baseline descriptive data were presented as frequencies
(percentages) for categorical variables and as the means with
standard error or median with range for continuous data. The
associations between BMQ-subscales, Brief IPQ-subscales and
symptoms and a MARS <25-score at cycle 3, were analyzed
univariate by means of logistic regression with MARS <25-score
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as the dependent variable. Associations between symptoms at
cycle 1 and a decreased dose at the start of cycle 2 was
tested using the X2-test or Fisher’s exact test when appropriate.
Associations between reporting of symptoms and any adjustment
in dosing regimen (shortening of period of use of cycle 1,
delaying cycle 2 and/or adjusting during cycle 1 or at the
start of cycle 2) were tested in a similar way. The influence
of baseline characteristics as factors on dose reduction at the
start of any new cycle, and any adjustments in dosing regimen
during the study period, respectively, was tested using univariate
logistic regression. Factors tested significantly in univariate
analysis (p < 0.05) were included in a multivariate logistic
regression using forward selection. To test the relationship
between the AUC of a metabolite of capecitabine and a
patient-reported symptom at cycles 3 and 5, a Generalized
Estimating Equations (GEE) model was fitted with presence of
symptoms as the dependent variable and the AUC measured
at the same cycle as the independent variable. GEE was used
to take into account within-patient correlation between the
dependent variable at cycles 3 and 5. For all analyses, a two-tailed
significance level of 0.05 was used. P-values below this level were
considered statistically significant. The statistical analyses were
performedwith SPSS 20.0 forWindows (IBMCorp, Armonk, NY,
USA).
RESULTS
Baseline Characteristics
A total of 92 patients were included, of whom 87, 70, and 57
were still on treatment in the second week of cycles 1, 3, and
5, respectively. Supplementary Table S1 provides information on
the number of patients for whom data were available at each
time-point. All patients used capecitabine in the usual 3-week
cycle regimen. Baseline characteristics of the patients are listed
in Table 1. Patients (62% male, median age 64.4 years) had most
frequently a diagnosis of colorectal cancer (66/72%), 16 had
breast cancer (17%), four had pancreatic cancer (4%), and six
had another type of cancer (oesophageal, head-and-neck, and
unknown origin; 7%).
Treatment and Adjustments to the Dosing
Regimen
Themedian starting dose of capecitabine was twice daily 2000mg
(range: twice daily 1000–2650mg a day), corresponding with
a median dosing regimen of twice daily 988 mg/m2/d (range
0523–1305). The initial dosing regimen was adjusted at least once
in 62% of the patients. This could either be a dose reduction
(30%), dose increase (13%), shortening of the period of use
(21%), or delay (35%). In The type, frequency and time-points
of dose adjustments are described in detail in Supplementary
Table S2.
Medication Adherence
The adherence rate (implementation phase) could be calculated
for 67 patients (73%). For the remaining 27%, either the pill count
was missing or data from the pharmacy or medical file were
incomplete. Within the studied period the mean and median
TABLE 1 | Baseline characteristics.
Age (yr) median 64.4
Range 39.2–86.8
Sex (N (%))
Male 57 (62.0)
Female 35 (38.0)
Education (N (%))
Low level 25 (27.2)
Higher level 67 (72.8)
Living status (N (%))a
Living alone 16 (17.6)
Living together 75 (83.4)
Occupation (N (%))b
Paid work 25 (28.4)
No paid work 63 (71.6)
Co-medicationc
% of patients with co-medication 78.9
Number of medicines, median 2
Number of medicines, range 0–14
Initial capecitabine dose
Median (mg/m2/d) 1975
Range (mg/m2/d) 1046–2609
Median (mg/d) 4000
Range (mg/d) 2000–5300
Type of cancer (N (%))
Colorectal cancer 66 (71.7)
- Adjuvant 17 (18.5)
- Metastatic 49 (53.3)
Breast cancer 16 (17.4)
Gastric cancer 4 (4.3)
Other 6 (6.5)
Capecitabine regimen (N (%))
Single agent 27 (29.3)
Combination 65 (70.7)
Abbreviations: yr, years; mg/d, milligrams per day; mg/m2/d, milligrams, per square
meters per day.
aOne missing.
bFour missings.
cTwo missings.
adherence rate were 99.3 and 100.0%, respectively. Most patients
(91%) had an adherence rate of≥95–≤105%. In five patients (7%)
the adherence rate was <95% and in two of them (3%) this was
<90%. One patient had an adherence rate >105%.
Self-reported adherence measured with MARS is presented
in Table 2. Non-adherence increased over time. The percentage
of patients reporting non-adherence on any of the five MARS
statements was 16% at cycle 1, 23% at cycle 3, and 29% at cycle
5. The most common statement was “forgetting to take it” (12,
20, and 26% at respectively cycles 1, 3, and 5). Over-adherence
was mentioned by one patient at cycle 5.
There were three blood samples (1.9%) without any detectable
concentrations of capecitabine, 5′-DFCR, 5′-DFUR, and 5-FU,
while the patient stated to have taken the last capecitabine within
the period 12 h–20 min prior to blood collection. These samples
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TABLE 2 | Use of capecitabine, quality of life, and patients’ beliefs.
T0 Cycle 1a Cycle 3a Cycle 5a
N = 92 N = 77 N = 66 N = 56
ADHERENCE (MARS)
MARS < 25 score (%) n.a. 15.7 23.1 28.8
I forget to take it (%) n.a. 12.2 20.0 25.5
I alter the dose (%) n.a. 2.8 6.2 9.3
I stop taking it for a while (%) n.a. 4.3 1.5 5.6
I decide to miss out a dose (%) n.a. 4.2 3.1 9.4
I take less than instructed (%) n.a. 1.4 1.5 3.8
OVERUSE
I use more than prescribed (%) n.a. 0.0 0.0 1.9
Reminder method (%) n.a. 61.5 66.2 73.2
Incorrect timing of intake (%) n.a. 13.2 32.8 24.1
Intake with grapefruit (%) n.a. 0.0 1.6 3.6
SF-12 (MEAN ± SD)
Physical component (0–100) 37.1 ± 9.3 38.4 ± 9.9 37.7 ± 9.9 37.4 ± 11.1
Mental component (0–100) 47.1 ± 7.5 48.5 ± 6.7 49.0 ± 5.8 50.4 ± 5.4
BMQ (MEAN ± SD)
General overuse (4–20) 10.4 ± 2.4 10.5 ± 2.9 10.6 ± 2.6 10.6 ± 2.3
General harm (4–20) 9.7 ± 2.52 10.1 ± 2.5 9.5 ± 2.5 9.8 ± 2.5
Specific necessity (5–25) 19.5 ± 3.3 19.5 ± 3.6 19.2 ± 3.9 18.6 ± 4.1
Specific concern (5–25) 14.3 ± 4.0 14.2 ± 3.9 14.0 ± 4.4 14.1 ± 3.6
Nec-conc differential (−20–20) 5.1 ± 5.3 5.1 ± 4.6 5.2 ± 5.2 4.6 ± 5.5
BRIEF IPQ (MEAN ± SD)
Consequences (0–10) 6.8 ± 2.6 6.8 ± 2.8 6.8 ± 2.5 6.6 ± 2.4
Time line (0–10) 7.4 ± 2.8 7.5 ± 2.6 7.4 ± 2.9 7.1 ± 3.1
Personal control (0–10) 4.6 ± 2.9 4.5 ± 2.6 4.5 ± 3.0 4.3 ± 3.0
Treatment control (0–10) 7.8 ± 1.8 7.4 ± 2.1 7.8 ± 1.8 8.0 ± 1.6
Identity (0–10) 5.1 ± 2.9 5.0 ± 2.8 5.8 ± 3.0 5.5 ± 2.9
Concern (0–10) 7.3 ± 2.4 7.6 ± 2.3 6.8 ± 2.8 6.8 ± 2.4
Understanding (0–10) 6.1 ± 2.9 5.9 ± 3.1 5.9 ± 3.1 6.1 ± 3.0
Emotional response (0–10) 4.9 ± 2.8 4.8 ± 2.9 4.7 ± 2.5 4.5 ± 2.6
Abbreviations: sd, standard deviation; MARS, Medication Adherence Report Scale; SF-12, SF-12 Health Survey; BMQ, Beliefs about Medicines Scale; Brief IPQ, Brief Illness Perception
Questionnaire. aMeasured in week 2 of cycle. Missings excluded in frequency analyses.
belonged to three different patients (two at cycle 3 and one at
cycle 5).
The majority of patients (>60%) reported to use a reminder
method to support the capecitabine intake. At cycles 1, 3, and
5, respectively 13, 33, and 24% of patients did not always time
their capecitabine with the intake of food as recommended
(Table 2).
At the end of the observation period, 35 patients had
discontinued treatment. Of these patients, 16 filled out the
questions about discontinuation: 7 (44%) reported side-effects
as the reason to stop treatment with capecitabine, 4 (25%)
discontinued because of lack of clinical efficacy, the remaining
for other or unknown reasons. For 11 (69%) of these 16
patients, physicians indicated the same reason to discontinue.
Physicians reported progression in 8 (50%) of patients and
adverse events in 4 (25%). Most patients (82%) indicated
that treatment was discontinued on the initiative of their
physician.
Patients’ Beliefs, Attitude, and Quality of
life
Table 3 shows the mean scores of items on SF-12, BMQ, and
Brief IPQ at baseline, as well as in week 2 of cycles 1, 3, and
5. The BMQ classification into four attitudinal groups based on
the patients’ responses at baseline was: 50.0% accepting (high
necessity, low concerns), 44.0% ambivalent (high necessity, high
concerns), 3.6% indifferent (low necessity, low concerns), and
2.4% skeptical (low necessity, high concerns).
Patient-Reported Symptoms
Patient-reported symptoms at baseline and in week 2 of cycles
1, 3, and 5 are listed in Table 3. The majority of patients (79%)
reported any fatigue at baseline, which was severe in 27% of
patients in cycle 1 only. HFSwas themost severe symptomduring
treatment of which the prevalence substantially increased over
time. Any HFS and severe HFS increased from, respectively, 26
and 7% at baseline to 95 and 53% of patients in cycle 5.
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TABLE 3 | Patient-reported symptoms.
% patients with any symptom % patients with severe* symptom
T0 Cycle 1a Cycle 3a Cycle 5a T0 Cycle 1a Cycle 3a Cycle 5a
N 92 77 66 56 92 77 66 56
Hand-foot syndrome 26.4 64.4 76.9 94.5 6.9 6.8 33.8 52.7
Fatigue 78.7 83.1 87.7 91.1 0 27.3 0 0
Flatulence 42.5 61.3 65.6 67.9 2.3 10.7 14.1 13.2
Change of taste 22.7 53.9 54.7 65.5 2.3 9.2 9.4 12.7
Skin problems 11.4 27.6 38.5 61.8 0 2.6 7.7 12.7
Dry mouth 34.1 44.0 52.3 61.8 0 6.7 7.7 10.9
Nausea 20.9 49.3 45.2 54.5 2.3 9.6 6.5 7.3
Breathing problems 33.7 40.3 46.2 53.7 2.3 2.6 6.2 7.4
Stomach ache 33.0 35.5 42.2 51.9 4.5 9.2 6.3 11.1
Rhinorrhea 27.3 32.9 33.8 50.9 0 3.9 4.6 1.9
Muscular pain 44.9 43.4 51.5 50.9 7.9 10.5 13.6 9.4
Loss of appetite 43.3 51.9 40.6 48.1 6.7 15.6 9.4 7.4
Diarrhea 21.8 41.9 35.5 43.6 0 2.7 4.8 7.3
Nail problems 7.1 8.0 23.8 43.6 1.2 0 3.2 7.3
Eye problems 10.2 18.4 39.1 43.4 0 1.3 4.7 11.3
Dizziness 16.1 30.7 37.5 40.7 1.1 0 4.7 5.6
Headache 16.1 33.8 34.9 37.0 1.1 4.1 3.2 7.4
Insomnia 40.9 32.9 41.5 37.0 3.4 9.2 6.2 3.7
Constipation 38.8 36.0 36.5 36.4 5.9 5.3 9.5 7.3
Depression 40.2 38.2 38.5 36.4 4.6 6.6 0 1.8
Weight loss 39.8 47.4 47.6 29.6 2.3 11.8 7.9 3.7
Alopecia 4.6 10.5 27.7 26.4 2.3 3.9 4.6 5.7
Mucositis 5.7 13.3 12.7 25.5 0 1.3 1.6 1.8
Fever 12.6 16.0 17.2 16.7 0 4.0 4.7 0
Oedema 9.2 9.3 23.1 16.4 1.1 1.3 4.6 3.6
Symptoms presented in order of prevalence during cycle 5.
*All symptoms scored as “a lot” and “very much” were considered “severe.”
aSymptoms measured in week 2 of cycle. Missings excluded in frequency analyses.
Exposure to Metabolites
Baseline characteristics required for the pharmacokinetic
analyses (length, weight, BSA, creatinine, creatinine clearance,
AF, and capecitabine doses) are listed in Table 4. A total of 160
blood samples were collected. Three samples were excluded
because they were collected within 20 min after intake, and
three samples because of an unknown time-point of the
last capecitabine intake. In three samples not any detectable
metabolite was measured. Furthermore, 15 samples were
collected more than 12 h after the last capecitabine intake.
The median capecitabine dose was 995, 997, and 988 mg/m2
twice daily at cycle 1, 3, and 5, respectively. The median AUCs
(mg∗h/L) in cycle 1 of 5′-DFUR, 5-FU, and FBAL were 14.4,
0.86, 22.6, respectively.
Factors Associated with Non-Adherence
(Implementation Phase)
As only six patients (9%) had an adherence rate of ≤95%
or >105% (measured with the pill count) no factors, such as
patients’ beliefs and attitude, patient-reported symptoms, or
exposure to metabolites, could be related with non-adherence.
At all cycles, the mean MARS scores of these six patients were
slightly lower compared to the mean MARS scores of the total
study population (24.0 vs. 24.7 at cycle 1, 23.7 vs. 24.6 at cycle
3, and 23.3 vs. 24.5 at cycle 5). There were no associations
between patients’ beliefs (BMQ-subscales or Brief IPQ-subscales)
and scores on the MARS-questionnaire.
Factors Associated with Dose Adjustments
Preceding a dose reduction or any adjustment of the dosing
regimen, patients reported several symptoms more frequently as
compared to patients who continued their treatment as originally
prescribed (Supplementary Table S2). Patients who started cycle
2 with a reduced dose reported more often depression in week 2
of cycle 1 (p = 0.025). Skin problems were among the symptoms
necessitating any adjustment of the dosing regimen till start of
cycle 2 (p = 0.004), but these symptoms did not significantly
result in dose reduction at start of cycle 2.
The following variables at baseline were positively associated
with the occurrence of any adjustment to the dosing regimen
during the study period: male (OR 2.89, 95% CI: 1.21–6.91),
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TABLE 4 | Characteristics pharmacokinetics.
All samples Cycle 1a Cycle 3a Cycle 5a
N = 58 N = 41 N = 38
Length (cm) Median 172 173 172
Range 156–195 156–196 156–196
Weight (kg) Median 77.5 77.9 77.0
Range 51–130 50–112 49.5–124
BSA (m2) Median 1.90 1.87 1.87
Range 1.49–2.44 1.49–2.44 1.47–2.40
Creatinine (µmol/l) Median 77.5 74 78.5
Range 51–146 52–289 36–150
Creatinine
clearance (ml/min)
Median 95.1 100.0 95.7
Range 48.4–184.0 20.3–156.3 45.9–194.5
ALP (U/l) Median 82.5 73.0 84.0
Range 38–373 42–779 39–297
Dose capecitabine
(mg/2dd)
Median 2000 2000 1800
Range 1000–2650 1150–2500 1000–2250
Dosing regimen
(mg/m2/2dd)
Median 996 997 975
Range 524–1305 605–1278 539–1093
AUC 5′-DFUR
(mg* h/L)b
Mean ± sd 14.39 ± 3.10 13.85 ± 4.02 12.68 ± 4.03
Median 14.39 13.33 12.47
Range 6.97–22.28 7.45–26.26 5.03–26.16
AUC 5-FU (mg*
h/L)b
Mean ± sd 0.953 ± 0.449 1.043 ± 0.448 1.180 ± 0.314
Median 0.860 0.936 1.106
Range 0.368–2.697 0.447–2.228 0.314–3.632
AUC FBAL (mg*
h/L)b
Mean ± sd 22.71 ± 4.28 21.23 ± 3.59 20.18 ± 4.18
Median 22.63 21.37 20.78
Range 13.48–31.94 15.56–30.12 11.46–28.64
Abbreviations: sd, standard deviation; BSA, body surface area; ALP, alkaline phosphatase;
U, units; 2dd, twice daily; AUC, area under the curve; 5′-DFUR= 5′-deoxy-5-fluorouridine;
5-FU, 5-fluorouracil; FBAL, α-fluoro-β-alanine.
a In week 2 of cycle.
bUndetectable plasma concentrations were excluded.
the number of co-medication (OR 1.16; 95% CI: 1.01–1.31) and
five out of eight subscales of the Brief IPQ; consequences (OR
1.24, 95% CI: 1.03–1.48), time line (OR 1.26, 95% CI: 1.04–
1.46), identity (OR 1.28, 95% CI: 1.04–1.58), concern (OR 1.19,
95% CI: 1.02–1.40) and emotional response (OR 1.31, 95% CI:
1.11–1.57) (Supplementary Table S3). In multivariate analysis a
higher number of co-medication (OR 1.19, 95% CI: 1.03–1.39)
and emotional response to the disease (OR 1.32, 95% CI: 1.10–
1.59) were associated with the probability of an adjustment of any
kind (Supplementary Table S4). Multivariate analyses of factors
of the dependent variable “dose reduction at the start of any new
cycle” did not result in a significant association.
Associations Between the AUC of
Metabolites and Symptoms
The following relationships between the AUC of capecitabine
metabolites and patient-reported symptomsmeasured during the
same cycle were found: AUC 5′-DFUR and weight loss (OR 1.10,
95% CI: 1.01–1.19), AUC FBAL and HFS (OR 0.90, 95% CI: 0.83–
0.99), AUC FBAL and rhinorrhea (OR 1.21, 95% CI: 1.03–1.42),
AUC FBAL and weight loss (OR 1.09, 95% CI: 1.00–1.20), and
AUC FBAL and depression (OR 0.90, 95% CI: 0.82–0.99) (p <
0.05) (Supplementary Table S5).
DISCUSSION
The present study showed that adherence with the use of
capecitabine measured with a pill count method was high. Due
to the high adherence, factors related to non-adherence were not
found. The number of patients reporting non-adherence with
MARS, however, increased over time.
Assessing the adherence rate for capecitabine with our pill
count method revealed that only 8% of patients used less than
95% and one patient usedmore than 105% of the prescribed dose.
Other studies on capecitabine have also reported high rates of
adherence (Macintosh et al., 2007; Mayer et al., 2009; Regnier
Denois et al., 2011; Simons et al., 2011; Winterhalder et al., 2011;
Bhattacharya et al., 2012; Krolop et al., 2013; Patel et al., 2013;
Thivat et al., 2013; Walter et al., 2013; Timmers et al., 2014;
Zahrina et al., 2014; De Figueiredo and Forones, 2014). It is
not known if the reported non-adherence with capecitabine may
result in less efficacy. It should be noted that lowering the initially
prescribed dose in the course of treatment in case of toxicity
does not seem to compromise clinical efficacy in advanced breast
cancer (Cassidy et al., 2002; Leonard et al., 2011), suggesting
that some level of non-adherence may not largely affect
outcome.
Although, the adherence rate measured with a pill count
over the complete study period was high, non-adherence on
the basis of the measurement of plasma concentrations was
observed. There was an absence of any metabolite in three of 160
samples (1.9%), while the patients had reported to have taken
capecitabine in the period 20 min–12 h before blood collection.
These patients had detectable metabolite concentrations at other
time-points.
Self-reported non-adherence measured with MARS revealed
increasing rates of deviations over time from 15% in cycle 1 to
29% in cycle 5. “Forgetting to take pills,” which is considered
the main cause of unintentional non-adherence, was the most
frequently reported reason (Hugtenburg et al., 2013). Also
reports on intentional non-adherence (e.g., adjusting the dose
or deciding to skip a dose) increased over time. Experience of
adverse events may decrease quality of life, thereby influencing
patients’ decisions to skip and/or reduce doses. Decreasing
adherence over time has been described previously and is
especially relevant for longer term oral treatments. One third
of patient who discontinued treatment before finishing 5 cycles,
stated that side effects were a reason to discontinue. Therefore,
measures to support adherence and ameliorate adverse events
seem specifically relevant in on-going use and should be
incorporated in prolonged support of patients to optimize their
use of capecitabine.
The concerns and perceived necessity of medicationmeasured
with the BMQ showed that 50% of patients had an accepting
attitude toward capecitabine. As compared to patients with
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asthma, cardiac disease, depression, or diabetes (Tibaldi et al.,
2009), more capecitabine patients scored high on the concerns
(48 vs. 33%) and necessity (94 vs. 88%) scales. In non-small cell
lung cancer patients using erlotinib, we also found high scores
for the concerns and necessity scales on the BMQ (Timmers
et al., 2015). The seriousness of the disease seems to reflect the
differences in BMQ-scores with other patient groups. Although,
the relationship between BMQ-scores and adherence has been
established thoroughly (Horne et al., 2013), we did not find this
relation in our population, probably as a result of the small
amount of patients with non-adherence.
Patients experienced a variety of symptoms. HFS, fatigue
and gastro-intestinal problems (like flatulence, nausea, and
diarrhea), were reported most frequently. As many patients
already had symptoms at baseline, were pre-treated and/or used
capecitabine in combination with oxaliplatin or irinotecan, it
is difficult to differentiate between these factors and adverse
events from capecitabine. Since patients report subjective and
less specific complaints better than their clinicians (Trotti
et al., 2007), ideally patient-reported symptoms should be used
complementary to physicians’ scores (Basch et al., 2009, 2012).
Patient-reported outcomes (PRO) are crucial in patient-centered
care, especially in end-of-life care and palliative care where
symptom management and quality of life are most important
(Peppercorn et al., 2011). PRO to assess the actual benefit
patients retrieve from their treatment is increasingly being used
in oncology (Gaertner and Becker, 2014). In this respect, it
should be noted that the National Cancer Institute recently
published a PRO version of the common terminology criteria
for adverse events (PRO-CTCAE), which enables the assessment
of patient-reported symptoms in cancer clinical research
(Basch et al., 2014).
Adjustments in the dosing regimen made by the physician
occurred at least once in almost two third of the patients
(62%). Most common adjustments were delaying a next cycle
and reducing the dose of the next cycle, both occurring in
about one third of patients. Patient-reported symptoms were
collected in the second week of the cycle, because of which
we were not able to analyze the reasons for adjustments after
the rest period from the patient’s perspective. For physicians,
severe adverse events in the preceding treatment cycle as well
as the patient’s wish or complaints may be reasons to adjust
the dose. Depression was more frequently found in the cycle
prior to dose reduction. HFS and diarrhea, which are generally
physician’s reasons to adjust the dose (Walko and Lindley,
2005), were not reported more frequently in patients with
dose adjustment. In this respect, we were unable to take into
account severe symptoms only, because the number of patients
in our study was too small. Emotional response to the disease
and the number of co-medication were associated with the
occurrence of any adjustment of the dosing regimen during
the five treatment cycles. Co-medication is likely related with a
poorer health condition with a higher risk of adverse events. A
stronger emotional response to cancer may also be a reflection
of poorer health condition or may influence a physician’s
estimation of the level of discomfort caused by adverse
events.
We observed few relationships between patient-reported
symptoms and the AUC of capecitabine metabolites (AUC
5′-DFUR and weight loss, AUC FBAL and HFS, AUC FBAL
and rhinorrhea, AUC FBAL and weight loss, AUC FBAL and
depression). None of them have been observed by Gieschke et al.
(2003). It is well known that capecitabine clearance is subject
to considerable inter-individual variation (Regnier Denois et al.,
2011). HFS is a common side-effect of capecitabine which
causes serious discomfort to patients and can be the reason for
dose adjustment, discontinuation of therapy and may influence
medication adherence. Patients on DPD inhibitor-associated
fluoropyrimidine treatments, such as uracil/tegafur or S-1, only
occasionally experience HFS, which suggests that this adverse
event is caused by the metabolites of 5-FU (Yen-Revollo et al.,
2008). We, however, found an inverse relationship: a higher
AUC of FBAL was associated with a lower risk of HFS (OR
0.90, 95% CI: 0.83–0.99). This inconsistency may be caused by
the low incidence of severe HFS in our small population. For
5-FU, therapeutic drug monitoring (TDM) may contribute to
reduce toxicity and improve response (Paci et al., 2014), but
TDM to optimize dosing of capecitabine does not seem to be
useful.
There are strengths and limitations to discuss. Unique is
that we longitudinally collected a wide range of variables to
explore the use of capecitabine in daily practice. However, the
number of patients was limited and some relevant information
was not collected (such as number of patients approached and
previous or concomitant use of medication). The variety of
variables and interrelationships may introduce risk of errors by
multiple testing. We did not adjust the significant p-value as our
intention was to broadly explore daily practice. Future research
using specific research questions may confirm the associations.
The adherence rate over the studied period was obtained with
a pill count method taking into account the dose adjustments
made by the physician during treatment. Furthermore, the
information was enriched with a self-report method by means
of MARS. A disadvantage of these methods is, that they do
not provide information on the timing of intake. Although, it
was not planned in the design of the study, we identified few
blood samples without detectable metabolite concentrations of
which it is likely that the patient was non-adherent at that
moment. The studied period lasted five cycles. As adherence is
decreasing over time, further research should focus on continued
use requiring prolonged follow-up. Another limitation of our
study is that we did not collect patient-reported symptoms
on the day preceding the next cycle, because of which we do
not know the reasons for dose adjustments from the patients’
perspective. Since the number of patients with an adherence
rate <95 or >105% was very low, we were not able to study
the influence of attitude or patient-reported symptoms on
adherence.
CONCLUSION
Adherence to capecitabine was generally high. The clinical
relevance of the small extent of non-adherence is uncertain.
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Medication adherence measured with self-reports (MARS)
decreased over time. Side effects were reported by one
third of patients as the reason to discontinue treatment.
Therefore, it appears that adverse event management is
important to support persistence. In addition, adherence
management to support implementation of correct capecitabine
use is specifically relevant in longer term treatment. With
the extending armamentarium of oral targeted anticancer
agents and prolonged treatment duration, we expect the
issue of medication adherence of increasing importance in
oncology.
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